| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Glioblastoma | D005909 | 27 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kotti T et al. | Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. | 2008 | Proc. Natl. Acad. Sci. U.S.A. | pmid:18685105 |
| Peleg AY et al. | Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. | 2008 | Proc. Natl. Acad. Sci. U.S.A. | pmid:18794525 |
| Mayoral JG et al. | NADP+-dependent farnesol dehydrogenase, a corpora allata enzyme involved in juvenile hormone synthesis. | 2009 | Proc. Natl. Acad. Sci. U.S.A. | pmid:19940247 |
| Caldwell GA et al. | Consequences of altered isoprenylation targets on a-factor export and bioactivity. | 1994 | Proc. Natl. Acad. Sci. U.S.A. | pmid:8108401 |
| Laezza C et al. | v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9811854 |
| Fisher JE et al. | Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9874784 |
| Casey PJ et al. | p21ras is modified by a farnesyl isoprenoid. | 1989 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2682646 |
| Stone KJ and Strominger JL | Inhibition of sterol biosynthesis by bacitracin. | 1972 | Proc. Natl. Acad. Sci. U.S.A. | pmid:4338587 |
| Jautelat M et al. | Natural-abundance 13C nuclear magnetic resonance spectra of terpenes and carotenes. | 1970 | Proc. Natl. Acad. Sci. U.S.A. | pmid:5263764 |
| Lopez-Medina E et al. | Candida albicans Inhibits Pseudomonas aeruginosa Virulence through Suppression of Pyochelin and Pyoverdine Biosynthesis. | 2015 | PLoS Pathog. | pmid:26313907 |